Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes
| Autor: | P. E. Beales, Paolo Pozzilli |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Male
Latent autoimmune diabetes of adults medicine.medical_specialty Endocrinology Diabetes and Metabolism Type 2 diabetes Rosiglitazone Mice Troglitazone Endocrinology Insulin resistance Mice Inbred NOD Diabetes mellitus Internal medicine Internal Medicine medicine Animals Hypoglycemic Agents Chromans NOD mice Type 1 diabetes business.industry Incidence medicine.disease Disease Models Animal Thiazoles Diabetes Mellitus Type 1 Female Thiazolidinediones business medicine.drug |
| Zdroj: | Diabetes/Metabolism Research and Reviews. 18:114-117 |
| ISSN: | 1520-7560 1520-7552 |
| Popis: | Background Thiazolidinediones (TZDs) are a recently introduced generation of drugs acting as receptor agonists to reduce insulin resistance and used currently in combination with other hypoglycaemic agents for the treatment of type 2 diabetes. In addition, TZDs possess anti-inflammatory properties that make them of interest for reducing the T-cell inflammation occurring in the islets in type 1 diabetes. Methods The action of TZD treatment on diabetes incidence in the non-obese diabetic (NOD) mouse was studied by investigating the effect of rosiglitazone (RGL) (400 mg/kg body weight by gavage) from 3 weeks of age (soon after weaning) onwards and comparing its effect to that of troglitazone (TGL) given by the same route. Results We found that RGL and TGL both significantly reduced diabetes incidence by >50% in the NOD mouse compared to litter-matched control NOD mice (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text